Incentivos y desincentivos de la industria farmacéutica privada para la I+D de nuevos medicamentos
AUTOR(ES)
Curcio, Pasqualina Curcio
FONTE
Cadernos de Saúde Pública
DATA DE PUBLICAÇÃO
2008-10
RESUMO
The authors present a model with factors that influence research and development decisions by the pharmaceutical industry: risk of disease transmission and possibility of control; case-fatality and the presence of cure or treatments; income; number of persons who demand the medicine; and opportunity costs for the company. Companies tend to invest in markets with inelastic demand (highly contagious diseases with no possibility of controlling transmission and/or very lethal diseases without treatment) and/or where there is a large population or high per capita income. Companies tend not to invest in markets where marginal costs exceed marginal income, particularly when costs increase permanently as a consequence of rising opportunity costs generated by foregoing profit in other markets. In such cases, policies to subsidize R&D are not effective, and policies must be orientated towards strengthening basic and applied research by public institutions.
Documentos Relacionados
- La política farmacéutica nacional en Colombia y la reforma de la seguridad social: acceso y uso racional de medicamentos
- La industria farmacéutica y la sostenibilidad de los sistemas de salud en países desarrollados y América Latina
- Ações judiciais: estratégia da indústria farmacêutica para introdução de novos medicamentos
- Descentralización y participación en salud: nuevos aportes para la discusión
- Discurso médico y estrategias de marketing de la industria farmacéutica en los procesos de medicación de la infancia en Argentina